High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study
- 1 June 2004
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 44 (3) , 363-368
- https://doi.org/10.1016/j.lungcan.2003.12.004
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trialThe Lancet, 2001
- A dose escalation study of weekly docetaxel in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2000
- Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinomaAnnals of Oncology, 1999
- Front-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II TrialJournal of Clinical Oncology, 1999
- Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer?: Pro:European Journal Of Cancer, 1998
- Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.Journal of Clinical Oncology, 1998
- Fatal pulmonary toxicity resulting from treatment with gemcitabineCancer, 1997
- Docetaxel and interstitial pulmonary injuryAnnals of Oncology, 1997
- Advanced breast cancer: a phase II trial with gemcitabine.Journal of Clinical Oncology, 1995
- Reporting results of cancer treatmentCancer, 1981